

371

⑩  **Europäisches Patentamt**
European Patent Office
Office européen des brevets

⑪ Publication number: **0 073 657**
B1

⑫ **EUROPEAN PATENT SPECIFICATION**

- ⑬ Date of publication of patent specification: **27.12.90** ⑭ Int. Cl.⁵: **C 12 N 15/81, A 61 K 39/29, C 12 N 15/33**
⑮ Application number: **82304513.3**
⑯ Date of filing: **26.08.82**

⑰ Preparation of hepatitis B surface antigen in yeast.

- | | |
|--|---|
| <p>⑱ Priority: 31.08.81 US 298236</p> <p>⑲ Date of publication of application: 09.03.83 Bulletin 83/10</p> <p>⑳ Publication of the grant of the patent: 27.12.90 Bulletin 90/52</p> <p>㉑ Designated Contracting States: AT BE CH DE FR GB IT LI LU NL SE</p> <p>㉒ References cited:
EP-A-0 013 828
EP-A-0 020 251
EP-A-0 072 318
FR-A-2 270 892</p> <p>NATURE, vol. 280, 1979, pp. 815-819
THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 255, 1980, pp. 12073-12080</p> <p>Recombinant DNA, Proceedings 3rd Cleveland Symposium on Macromolecules, 22-26 June 1981 (Walton Ed.), pp. 185-197, Elsevier Publ. Co., Amsterdam, NL</p> | <p>㉓ Proprietor: GENENTECH, INC.
460 Point San Bruno Boulevard
South San Francisco California 94080 (US)</p> <p>㉔ Inventor: Hitzeman, Ronald A.
1251 Rosita
Pacifica California 94044 (US)
Inventor: Levinson, Arthur D.
2931 Frontera Way
Burlingame California 94010 (US)
Inventor: Yansura, Daniel G.
125 Pioche
San Francisco California 94134 (US)</p> <p>㉕ Representative: Armitage, Ian Michael et al
MEWBURN ELLIS & CO. 2/3 Cursitor Street
London EC4A 1BQ (GB)</p> <p>㉖ References cited:
Biological Products for Viral Diseases (P.A. Bachmann) 1981, pp. 45-69, Taylor & Francis Ltd., London, GB</p> <p>SCRIP, no. 616, 12.8.81, p. 14
THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 256, 1981, pp. 6975-6983</p> |
|--|---|

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European patent convention).

EP 0 073 657 B1

Description

This invention relates to the use of a recombinant DNA technology for the production of mature hepatitis B surface antigen (HBsAg) in yeast organisms for use in the preparation of vaccines against hepatitis B virus (HBV). In one aspect, the present invention relates to the construction of microbial expression vehicles containing DNA sequences encoding mature hepatitis B surface protein antigens operably linked to expression effecting promoter systems and to the expression vehicles so constructed. In another aspect, the present invention relates to yeast organisms transformed with such expression vehicles, thus directed in the expression of the DNA sequences referred to above. In yet other aspects, this invention relates to the means and methods of converting the end products of such yeast expression to entities, such as vaccines, useful against hepatitis B virus. In preferred embodiments, this invention provides for particular expression vectors that utilize potent yeast promoters and DNA sequences distal to that encoding the hepatitis B surface antigen protein which, in combination, provide attractive yields of desired protein, produced in particle form of about 22 nm, and containing antigenic determinant(s) of hepatitis B virus.

The publications and other materials thereof used to illuminate the background of the invention, and in particular cases, to provide additional details respecting its practice are incorporated herein by reference, and for convenience, are numerically referenced in the following text and grouped in the appended bibliography.

Hepatitis B virus

Hepatitis B (serum hepatitis) virus is transmitted among humans and manifests as chronically debilitating infections which can result progressively in severe liver damage, primary carcinoma and death. In most cases, complete recovery from hepatitis B infections can be expected; however, large segments of the population, especially in many African and Asian countries, are chronic carriers with the dangerous potential of transmitting the disease pandemically.

Hepatitis is caused by a virus vector (hepatitis B virus or HBV) which in its whole state—the so-called Dane particle—represents the virion and consists of a 27 nm nucleocapsid enclosing a DNA molecule and an envelope surrounding the nucleocapsid. Proteins associated with the virion include the core antigen (HBcAg), a DNA polymerase and the surface antigen (HBsAg) which has been found in serum of infected and carrier humans. Antibodies to HBsAg have also been found in serum HBV infected people. It is believed that HBsAg is the HBV antigen that can induce immunogenic production of antibody (anti-HBs) and thus it would be the principal in an HBV vaccine. Attention is directed to: Dane *et al.*, *Lancet* 1970 (II), 695 (1970); Hollinger *et al.*, *J.*

Immunology 107, 1099 (1971); Ling *et al.*, *J. Immunology* 109, 834 (1972); Blumberg, *Science* 197, 17 (1977); Peterson *et al.*, *Proc. Nat. Acad. Sci (USA)* 74, 1530 (1977) and *Viral Hepatitis, A Contemporary Assessment of Etiology, Epidemiology, Pathogenesis and Prevention*. (Vyas *et al.*, eds.) Franklin Institute Press, Philadelphia, 1978, each of which is hereby incorporated by this reference to further illustrate the background of this invention.

HBsAg is present in infected plasma predominantly in the form of spherical particles having diameters ranging from about 16 to 25 nm—the so-called "22 nm particle". These are thought to represent a noninfectious viral envelope. Because antibodies against HBsAg are protective against HBV infection, these non-infectious particles can effectively be used as a vaccine.

Inasmuch as the hepatitis B virus has not been infectious in cell culture and can only be obtained from infected humans or higher primates, means have not been available for obtaining and maintaining sufficient supplies of HBV for use in producing antigens for immunization against HBV.

The present invention provides the means and methods for producing a vaccine effective against HBV. By means of recombinant DNA technology, the gene encoding mature HBsAg was inserted with appropriate translational start and stop signals under the control of an appropriate expression promoter into a replicable expression vector and the latter used to transform yeast cells. The cells, thus genetically directed, produced HBsAg directly and in particle form which, when purified, is suitable to immunize against HBV.

The conflicting European patent application EP—A—0 072 318 disclosed *inter alia* yeast expression vectors in which the DNA sequence coding for the HBsAg lacks all of the bases of the 5'-untranslated region. However, this particular embodiment enjoys a later effective date than in the present application.

Recombinant DNA technology

With the advent of recombinant DNA technology, the controlled microbial production of an enormous variety of useful polypeptides has become possible. Many mammalian polypeptides, such as human growth hormone and leukocyte interferons, have already been produced by various microorganisms. The power of the technology admits the microbial production of an enormous variety of useful polypeptides, putting within reach the microbially directed manufacture of hormones, enzymes, antibodies, and vaccines useful against a wide variety of drug-targeting applications.

A basic element of recombinant DNA technology is the plasmid, an extrachromosomal loop of double-stranded DNA found in bacteria oftentimes in multiple copies per cell. Included in the information encoded in the plasmid DNA is that required to reproduce the plasmid in daughter cells

(i.e., a "replicon" or origin of replication) and ordinarily, one or more phenotypic selection characteristics, such as resistance to antibiotics, which permit clones of the host cell containing the plasmid of interest to be recognized and preferentially grown in selective media. The utility of bacterial plasmids lies in the fact that they can be specifically cleaved by one or another restriction endonuclease or "restriction enzyme", each of which recognizes a different site of the plasmid DNA. Thereafter heterologous genes or gene fragments may be inserted into the plasmid by endwise joining at the cleavage site or at reconstructed ends adjacent to the cleavage site. Thus formed are so-called replicable expression vehicles.

DNA recombination is performed outside the microorganism, and the resulting "recombinant" replicable expression vehicle, or plasmid, can be introduced into microorganisms by a process known as transformation and large quantities of the recombinant vehicle obtained by growing the transformant. Moreover, when the gene is properly inserted with reference to portions of the plasmid which govern the transcription and translation of the encoded DNA message, the resulting expression vehicle can be used to direct the production of the polypeptide sequence for which the inserted gene codes, a process referred to as expression.

Expression is initiated in a DNA region known as the promoter. In the transcription phase of expression, the DNA unwinds exposing it as a template for initiated synthesis of messenger RNA from the DNA sequence. The messenger RNA is, in turn, bound by ribosomes, where the messenger RNA is translated into a polypeptide chain having the amino acid sequence encoded by the mRNA. Each amino acid is encoded by a nucleotide triplet or "codon" which collectively make up the "structural gene", i.e., that part of the DNA Sequence which encodes the amino acid sequence of the expressed polypeptide product. Translation is initiated at a "start" signal (ordinarily ATG, which in the resulting messenger RNA becomes AUG). So-called stop codons define the end of translation and, hence, the production of further amino acid units. The resulting product may be obtained by lysing the host cell and recovering the product by appropriate purification from other bacterial proteins.

In practice, the use of recombinant DNA technology can express entirely heterologous (not ordinarily found in, or produced by, a given micro-organism), polypeptides—so-called direct expression—or alternatively may express a heterologous polypeptide fused to a portion of the amino acid sequence of a homologous (found in, or produced by, the corresponding wild-type microorganism) polypeptide. In the latter cases, the intended bioactive product is sometimes rendered bioinactive within the fused, homologous/heterologous polypeptide until it is cleaved in an extracellular environment. See, e.g., British Patent Publ. No.

2 007 676 A and Wetzel, *American Scientist* 68, 664, (1980).

If recombinant DNA technology is to fully sustain its promise, systems must be devised which optimize expression of gene inserts, so that the intended polypeptide products can be made available in controlled environments and in high yields.

British Patent Publication 2034323A, published June 4, 1980, describes the isolation of the HBV genome comprising about 3200 nucleotides and the incorporation of this DNA into a vector taking advantage of an EcoRI digest and subsequent ligation. It is stated that the resultant cloned HBV-DNA can be labelled and used as a probe to detect Dane particles in serum and that the vector could be used to express a polypeptide containing a hepatitis B protein fragment.

In a related article from the same laboratories (*Proc. Natl. Acad. Sci (USA)* 77, 4549 (1980)), it is reported that tandem cloned hepatitis B genomes were introduced into mouse cells and integrated in to the mouse chromosome. Polypeptide identified as hepatitis surface antigen was excreted from the cells as particles similar to those found in the sera of infected humans.

European Patent application Publication No. 13828 describes the production of HBV core antigen by read-through translation of an mRNA transcript from the genomic DNA. No surface antigen was detected.

In European Patent Application Publication No. 20251 there is described the production in *E. coli* of a fusion protein purportedly containing a portion of the surface antigen protein of HBV. Because the surface antigen determinants were present as a fusion protein, the structure could not be native; hence, the reported low immunological activity.

The present invention is based upon the discovery that recombinant DNA technology can be used to successfully and efficiently produce the mature hepatitis B surface antigens, directly and in discrete particle form, a product that is suitable for use in conferring immunogenicity to hepatitis B virus in a susceptible human or for preparing a vaccine for such use. The product is produced in a eukaryotic host—yeast—and thus carries the advantages such systems confer on corresponding, proteinaceous products, to wit, glycosylation and sugar and lipid association more closely related to human produced proteins versus bacterial produced proteins whose hosts are incapable of such sophisticated processing. In addition, the eukaryotic yeast cells tolerate the protein product better than prokaryotic systems, doubtless increasing expression levels and yields significantly over bacterial systems, in which the hepatitis protein per se proved lethal.

The present invention comprises the mature hepatitis B surface antigen (HBsAg) produced and the methods and means of its production. Specifically, the present invention is directed to HBsAg in particle form comprising

immunogenic determinant(s) of hepatitis B virus, produced in yeast. The HBsAg hereof is produced in discrete particle form, devoid of any additional, fused polypeptide artifact, whether encoded by another portion of the HBV genome or by DNA homologous to the yeast strain employed. The present invention is further directed to replicable DNA expression vehicles harboring gene sequences encoding HBsAg in directly expressible form. Further, the present invention is directed to yeast strains transformed with the expression vehicles described above and to microbial cultures of such transformed yeast strains, capable of producing HBsAg. In still further aspects, the present invention is directed to various processes useful in preparing said HBsAg gene sequences, DNA expression vehicles, yeast strains and cultures and to specific embodiments thereof. Still further, this invention is directed to the use of thus produced HBsAg for the preparation of vaccines useful to confer immunogenicity to HBV in susceptible humans, to such vaccines and to the method of using them to inoculate and confer immunogenicity to HBV in susceptible humans.

The preferred promoter herein is one tailored from the yeast 3-phosphoglycerate kinase (PGK) promoter region which is described *infra*. The PGK gene was analyzed for restriction sites which would be useful for sequencing. DNA sequence analysis around one of these restriction sites indicated that translation beginning with a specific ATG would yield a protein whose N-terminal amino acids corresponded to the same N-terminal amino acids of human and horse PGK, this flanking DNA being considered the yeast PGK promoter region. The PGK promoter region was analyzed for a region which would logically support a unique restriction site. A primer repair reaction was carried out and this unique site was placed at the 3' end of the PGK promoter region. This unique site allowed the PGK promoter region to effect the direct expression of the thus fused gene in yeast.

A yeast/bacteria shuttle plasmid, pCV13 (or YEp13) described *infra*, had certain restriction fragments removed. Replacement of these fragments by PGK promoter region fused to surface antigen allowed reclosure of the vector. This vector was used to transform yeast which were grown up under customary fermentation conditions and permitted to produce the desired HBsAg product. Recovery of product followed by breaking open the transformed yeast. Supernatants from centrifuged solution were used as a substrate in hepatitis B surface antigen radioimmune assays.

A particular DNA sequence, found to be suitable herein as a transcription terminator, was placed after the gene sequence encoding HBsAg in order to terminate mRNA synthesis and provide a Poly A addition site for proper mRNA processing and translation. This terminator is based upon the 232 bp *Hind* III-to-*Bgl* II restriction fragment from the *Trp1* gene contained in pFRL4

(12). This fragment was isolated containing some coding sequence from the yeast *TRP1* gene and the 3'-flanking sequence required for proper transcription termination and polyadenylation. This terminator fragment was fused via its *Hind* III site to the *Hind* III site of the HBsAg gene. Transcription of the HBsAg gene by a fused yeast promoter in yeast is designed to terminate in the fused *TRP1* terminator fragment.

pCV13(1) contains the ampicillin and tetracycline resistance genes allowing for plasmid selection in *E. coli*, an *E. coli* origin of DNA replication, the *LEU2* gene allowing for selection of the plasmid in yeast and the 2 (micron) origin allowing for DNA replication of the plasmid in yeast. This plasmid is found in the nucleoplasm of transformed yeast. The small *Hind* III-to-*Bam* HI fragment from the tetracycline resistance gene was removed from the vector. The resulting large vector fragment was then ligated with the 1.6 kbp *Hind* III-to-*Eco* RI assembled PGK promoter fragment and a 1.1 kbp *Eco* RI-to-*Bgl* II HBsAg/*TRP1* terminator fragment so as to produce the pYeHBs vector in Figure 6. This HBsAg expression vector was constructed to have the PGK promoter fragment initiate transcription of the HBsAg structural gene and then terminate this transcript in the *TRP1* terminator previously fused to the HBsAg gene.

Preferred embodiments of the invention will now be described in greater detail with reference to the accompanying drawings in which:

Figure A depicts the construction of plasmid pHSG4 harbouring HBsAg DNA.

Figure 1 schematically illustrates the restriction map of the 3.1 kbp *Hind* III insert of vector pB1 from which the PGK promoter was isolated. Indicated is the insertion of an *Eco* RI site and an *Xba* I site in the 5'-flanking DNA of the PGK gene.

Figure 2 illustrates the 5'-flanking sequence plus the initial coding sequence for the PGK gene before insertion of *Xba* I and *Eco* RI sites.

Figure 3 schematically illustrates techniques used to insert an *Xba* I site at position—8 in the PGK promoter and to isolate a 39 bp fragment of the 5'-flanking sequence of PGK containing this *Xba* I end and a *Sau* 3A end.

Figure 4 schematically illustrates the construction of a 300 bp fragment containing the above 39 bp fragment, additional PGK 5'-flanking sequence (265 bp) from *Pvu* I to *Sau* 3A (see Fig. 1), and a *Eco* RI site adjacent to *Xba* I.

Figure 5 schematically illustrates the construction of the 1500 bp PGK promoter fragment (*Hind* III/*Eco* RI) which contains, in addition to the fragment constructed in Fig. 4, a 1300 bp *Hind* III to *Pvu* I fragment from PGK 5'-flanking sequence (see Fig. 1).

Figure 6 schematically illustrates the construction of an expression vector for hepatitis surface antigen in yeast, containing the modified PGK promoter, the HBsAg gene, and the terminator region of the yeast *TRP1* gene, as described in more detail herein.

Figure 7 depicts: A) sucrose gradient sedimen-

tation of yeast produced HBsAg compared with 22 mm particle and B) a corresponding CsCl gradient centrifugation thereof.

Yeast host organisms

In the preferred embodiments hereof, the expression system was placed in the plasmid pCV13 (1), which is capable of selection and replication in both *E. coli* and yeast, *Saccharomyces cerevisiae*. For selection in yeast the plasmid contains the *LEU2* gene (2) which complements yeast (allows for growth in the absence of leucine) containing mutations in this gene found on chromosomes III of yeast (3). The strain used here was the strain XV610-8C which has the genotype *a leu2 trp1 ade6 ade2 lys1 can1*. This strain is deposited in the American Type Culture Collection without restriction (ATCC No. 20622). However, it will be understood that any *Saccharomyces cerevisiae* strain containing a mutation which makes the cell *Leu2* should be an effective environment for expression of the plasmid containing the expression system. An example of another strain which could be used is ATCC No. 38626 which has the genotype, *a leu2-3 leu2-112 his4-519 can1* (4). This strain has two point mutations in *leu2* which restricts reversion and allows for tighter transformation of *Leu⁻* to *Leu⁺*.

Yeast promoters

The 5'-flanking DNA sequence from a yeast gene (for alcohol dehydrogenase 1) can promote the expression of a foreign gene (e.g. leukocyte interferon D) when placed in a plasmid used to transform yeast. Another yeast gene has been placed at the 3'-end of this construction to allow for proper transcription termination and polyadenylation in yeast. Indeed, we have shown that the mRNA transcript does end (3'-end) as expected in the termination/adenylation region of the yeast *TRP1* gene (Hitzeman et. al., *Nature*, 293, 717 (1981 (Ref. 12)). This promoter can be suitably employed in the present invention as well as others—cf. infra. In the preferred embodiments, the 5'-flanking sequence of the yeast 3-phosphoglycerate kinase gene (5) was placed upstream from the structural sequence for hepatitis surface antigen followed again by DNA containing the *TRP1* gene termination—polyadenylation signals.

Since both the yeast alcohol dehydrogenase I 5'-flanking sequence and the 3-phosphoglycerate kinase 5'-flanking sequence (infra) can function to promote expression of foreign genes in yeast, it seems likely that the 5'-flanking sequences of any highly-expressed yeast gene could be used for the expression of important gene products. Since under some circumstances yeast expresses up to 65 percent of its soluble protein as glycolytic enzymes (6) and since this high level appears to result from the production of high levels of the individual mRNAs (7), it should be possible to use the 5'-flanking sequences of any other glycolytic genes for such expression purposes—e.g., enolase, glyceraldehyde-3-phosphate dehydrogen-

ase, hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose-6-phosphate isomerase, 3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase, phosphoglucose isomerase, and glucokinase. Any of the 3'-flanking sequences of these genes could also be used for proper termination and mRNA polyadenylation in such an expression system—cf. *Supra*. Some other highly expressed genes are those for the acid phosphatases (8) and those that express high levels of production due to mutations in the 5'-flanking regions (mutants that increase expression)—usually due to the presence of a Tyl transposon element (9).

All of the genes mentioned above are thought to be transcribed by yeast RNA polymerase II (9). It is possible that the promoters for RNA polymerase I and III which transcribe ribosomal DNA, 5S DNA, and tRNA DNA (9, 10), may also be useful in such expression constructions.

Finally, many yeast promoters also contain transcriptional control so that they can be turned off or on by variation in growth conditions. Some examples of such yeast promoters are the genes that produce the following proteins: Alcohol dehydrogenase II, isocytochrome, said phosphatase, degradative enzymes associated with nitrogen metabolism, glyceraldehyde-3-phosphate dehydrogenase, and enzymes responsible for maltose and galactose utilization (9). Such a control region would be very useful in controlling expression of protein products—especially when their production is toxic to yeast. It should also be possible to put the control region of the 5'-flanking sequence with a 5'-flanking sequence containing a promoter from a highly expressed gene. This would result in a hybrid promoter and should be possible since the control region and the promoter appear to be physically distinct DNA sequences.

Detailed description

Identification of PGK promoter DNA

The six N-terminal amino acids of the 3-phosphoglycerate enzyme purified from humans are as follows:

1 — 2 — 3 — 4 — 5 — 6
SER—LEU—SER—ASN—LYS—LEU—

One of the translational reading frames generated from the DNA sequence of the 141 bp *Sau3A*-to-*Sau3A* restriction fragment (containing the internal *HincII* site; see PGK restriction map Figure 1) produces the following amino acid sequence.

1 — 2 — 3 — 4 — 5 — 6
MET—SER—LEU—SER—SER—LYS—LEU—

After removal of initiator methionine, it is seen the PGK N-terminal amino acid sequence has 5 of 6 amino acid homology with N-terminal amino acid sequence of human PGK.

This sequencing result suggested that the start

of the yeast PGK structural gene is coded for by DNA in the 141 bp *Sau3A* restriction fragment of pB1. Previous work (5) has suggested that the DNA sequences specifying the PGK mRNA may reside in this area of the *HindIII* fragment. Further sequencing of the 141 bp *Sau3A* fragment gives more DNA sequence of the PGK promoter (Shown in Figure 2).

Protocol: For the insertion of *XbaI/EcoRI* sites in the 5'-flanking sequence of the PGK gene and the Construction of a Promoter Fragment (see Fig. 1).

Step 1) Primer-repair reaction and cloning of 39 bp *XbaI*-to-*Sau3A* fragment (as shown in Fig. 3).

Step 2) Clone *PvuI*-to-*XbaI* partial promoter fragment (as shown in Fig. 4).

Step 3) Clone *EcoRI*-to-*EcoRI* promoter fragment (as shown in Fig. 5)—contains the *HindIII*-to-*EcoRI* promoter fragment used in Fig. 6 for construction of expression plasmid.

Insertion of *EcoRI* restriction site in the PGK promoter and promoter reassembly

The use of the PGK promoter for direct expression of heterologous genes in yeast requires that there be a restriction site on the 3' end of the PGK promoter fragment which does not contain the PGK initiator ATG. Figures 1, 3, 4 and 5 show how we inserted an *EcoRI* site in the PGK promoter. We used a primer-repair reaction (11) to first insert an *XbaI* site in the 3' end of promoter sequence. This *XbaI* sticky end was ligated to the *XbaI* site of a LEIFA (13) gene containing an *EcoRI* site adjacent to the *XbaI* site. This connection sequence at the 5' end of the LEIFA gene is as follows:

5'-TCTAGAATTCATG-3'
3'-AGATCTTAAGTAC-5'

This connection on the LEIFA gene is how an *EcoRI* site was inserted next to the *XbaI* site on the PGK promoter. Use of this *XbaI*-to-*EcoRI* connection allows for placement of structural genes containing either of these restriction ends at the 3' end of the PGK promoter for expression purposes.

Construction of expression vector Isolation of HBsAg structural gene

The structural gene coding for the HBsAg was recovered from a plasmid (pHBV-T-1A) containing the entire genome of HBV cloned into the *EcoRI* site of pBR322. This clone was obtained by methods similar to those recently published by Valenzuela et. al. (14) and (15).

The structural gene was modified in two ways 1) to incorporate a unique restriction site directly in front of the initial ATG methionine codon and 2) to blunt-end ligate the HBV *Hpa I* site located distal to the HBsAg gene to the filled in *EcoRI* site of pBR322. These two modifications to the DNA fragment containing the HBsAg structural gene was accomplished as described below:

1.) 50 µg of pHBV-T-1A DNA was first digested with *Hpa II* (80 units) in 200 µl reaction mixture

according to enzyme supplier's (BRL) reaction condition to obtain a 1.7 kb DNA fragment, in which the Initiation codon for the coding sequences of HBsAg was located close to the 5' end of the sense-strand (about 400 bp). The DNA was purified by electrophoresis on polyacrylamide gels. (PAGE). The purified *HpaI* fragment was then treated with λ exonuclease (2 units) in 100 µl reaction mixture (New England BioLab) for 30 minutes at 37°C. λ exonuclease is a 5' exonuclease which digests double stranded DNA. This reaction degraded the 5' half of the "sense-strand" DNA from HBsAg coding sequences and exposed the antisense strand for pairing with added primer. The λ exonuclease treated DNA was deproteinized and resuspended in 50 µl of reaction mixture containing 40 mM potassium phosphate buffer (pH 7.4), 1 mM DTT, 50 µg/ml BSA, 6 mM MgCl₂, 0.5 mM each of dNTPs, and 0.2 n mole of dATGGAGAACATC (³²p-labelled at 5' end by polynucleotide kinase). The mixture was first heated at 90°C for 1 minute, annealed at 0°C for 30 minutes and then incubated at 37°C for 3 hours in the presence of 2 units of *E. coli* DNA polymerase I Klenow fragment (16). The DNA polymerase synthesized DNA primed by the added primer and degraded single-stranded DNA with 3'-OH terminal and, therefore, created blunt ended DNA molecules. The resultant DNA was then deproteinized, digested with *XbaI* (45 units) at a site located within the HBsAg gene in a 100 µl reaction mixture and fractionated by PAGE. A 91 base pair DNA fragment containing the first 30 codons of HBsAg gene was isolated after autoradiographic detection (fragment A).

To create a unique restriction site site immediately 5' to the HBsAg gene, we took advantage of a derivative of the plasmid pBR322 (called pNCV) which contains a synthetic DNA segment with the sequence: AATTCTGCAG

GACGCTTAA

located at the *EcoRI* site. Incorporated into this synthetic DNA sequence is a *PstI* site. Ten µg of pNCV DNA was first cut with 24 units of *PstI* enzyme in a 100 µl reaction mixture and then treated with 2 units *E. coli* DNA polymerase I Klenow fragment in 50 µl reaction mixture as described above at 8°C for 1 hour. The DNA polymerase treatment removed the 4 base-pair 3' overhang created by *PstI* digestion to leave a blunt ended DNA with an intact *EcoRI* restriction site giving the fragment B, containing the origin of replication of pBR322. The blunt ended HBsAg gene fragment A prepared above was ligated to the *EcoRI* site of fragment B. This was accomplished in a three fragment ligation to create a plasmid pHS94. The third fragment (fragment C) was prepared as follows:

2.) The HBsAg gene from the plasmid pHBV-T-1A was cleaved with *HpaI* at a site distal to the HBsAg gene. The *HpaI* site was ligated to a *EcoRI* site of pBR322 previously filled in the DNA polymerase I Klenow fragment (16). This was

accomplished by subcloning the derivative of pBR322 to give pHS42. This plasmid was cleaved with *Xba*I (which cleaves at codon 31) and with *Bam*HI (which cleaves 375 base pairs from the *Eco*RI site of pBR322) to give a DNA fragment containing most of the HBsAg gene, ca. 150 base pairs distal to the HBsAg gene, and the promoter/operator and the first 200 base pairs of the tetracycline resistance gene. The DNA fragment C, bounded by *Xba*I and *Bam*HI was isolated by PAGE and used in the three fragment ligation described above to give the plasmid pHS94. (Fig. A).

Successful expression of a heterologous gene in yeast requires that transcription of that gene end with a sequence of DNA which allows for proper processing (polyadenylation) and transport of that transcript.

DNA restriction and modification enzymes

Restriction enzymes *Eco*RI and *Hind*III along with bacterial alkaline phosphatase were purchased from Bethesda Research Laboratories. DNA polymerase (Klenow fragment) was purchased from Boehringer-Mannheim. T₄ polynucleotide kinase, ATP and the deoxynucleoside triphosphates dATP, dGTP, dCTP and dTTP were purchased from PL Biochemicals. All other DNA restriction and metabolic enzymes were purchased from New England Biolabs. [γ -³²P]ATP was purchased from Amersham Corp. DNA restriction and metabolic enzymes were used in conditions exactly described by their respective manufacturers.

DNA preparation and transformation

Purification of covalently closed circular plasmid DNAs from *E. coli* (17) and yeast (18) plus the transformation of *E. coli* (19) and yeast (20, 21) were performed as previously described. *E. coli* miniscreens were done as previously described (22).

Strains and media

E. coli K-12 strain 294 (ATCC No. 31446) (23) was used for all bacterial transformations. Yeast strain XV610-8C having the genotype (*leu2 trp1 ade6* and/or *ade2, lys1 can1*) was used as yeast cloning host. (ATCC No. 20622).

LB (rich medium) was prepared as described by Miller (24) with the addition of either 20 μ g/ml ampicillin (Sigma) or 20 μ g/ml tetracycline (Sigma).

Restriction Map and partial sequencing of 3.1 kb insert of pB1

300 μ g of pB1 (5) was exhaustively digested with *Hind*III in a 500 μ l reaction volume, then electrophoresed on a 1 percent agarose preparative agarose (Sea Kem) gel. The 3.1 kb *Hind*III insert was cut from the ethidium stained gel, electroeluted (25), 2 \times extracted with equal volumes of buffer-saturated phenol and chloroform before ethanol precipitation. Portions of the resuspended DNA fragment was divided up

and subjected to restriction cuts with a group of different restriction enzymes to yield the partial restriction map depicted in Figure 1.

30 μ g of the purified 3.1 kb insert was cut with *Sau*3A then run on a 6 percent acrylamide gel. Fragments corresponding to the 265 bp and 141 bp were separately purified by electroelution as described above. Each DNA fragment was then subjected to DNA sequence analysis (25).

A portion of this DNA sequence is shown in Figure 2. Amino acids corresponding to the N-terminal amino acids of the PGK structural gene are printed above the DNA sequence.

Insertion of a restriction site in the PGK 5' promoter region

A synthetic oligonucleotide with the sequence 5'-ATTGTTGTAAA3' was synthesized by standard methods (26). 100 ng of this primer was labelled at the 5' end using 10 units of T₄ polynucleotide kinase in a 20 μ l reaction also containing 200 μ Ci of [λ ³²-P]ATP. This labelled primer solution was used in a primer-repair reaction designed to be the first step in a multi-step process to put an *Eco*RI restriction site in the PGK 5'-flanking DNA just preceding PGK structure gene sequence. The multistep process is explained below:

Step 1 (Figure 3)

Primer repair reactions and cloning of 39 bp *Xba*I-to-*Sau*3A PGK piece

100 μ g of pB1 was completely digested with *Hae*III then run on a 6 percent polyacrylamide gel. The uppermost band on the ethidium stained gel (containing PGK promoter region) was isolated by electroelution as described above. This 1200 bp *Hae*III piece of DNA was restricted with *Hinc*III then run on a 6 percent acrylamide gel. The 650 bp band was isolated by electroelution. 5 μ g of DNA was isolated. This 650 bp *Hae*III-to-*Hinc*III piece of DNA was resuspended in 20 μ l dH₂O, then mixed with the 20 μ l of the phosphorylated primer solution described above. This mixture was 1X phenol-chloroform extracted then ethanol precipitated. Dried DNA was resuspended in 50 μ l of H₂O and then heated in a boiling water bath for seven minutes. This solution was then quickly chilled in a dry ice-ethanol bath (10—20 seconds) then transferred to an ice-water bath. To this solution was added 50 μ l of a solution containing 10 μ l of 10X DNA polymerase I buffer (Boehringer Mannheim), 10 μ l of a solution previously made 2.5 mM in each deoxynucleoside triphosphate (dATP, dTTP, dGTP and dCTP), 25 μ l of dH₂O and 5 units of DNA Polymerase I, Klenow fragment. This 100 μ l reaction was incubated at 37°C for 4 hours. The solution was then 1X phenol-chloroform extracted, ethanol precipitated, dried by lyophilization then exhaustively restricted with 10 units of *Sau*3A. This solution was then run on a 6 percent acrylamide gel. The band corresponding to 39 bp in size was cut from the gel then isolated by electroelution, as described above. This 39 bp band has one blunt end and one

Sau3A sticky end. This fragment was cloned into a purified pFIFtrp69 vector (11). 10 µg of pFIFtrp69 was linearized with *XbaI*, 1X phenol chloroform extracted, then ethanol precipitated. The *XbaI* sticky end was filled in using DNA Polymerase I Klenow fragment in a 50 µl reaction containing 250 µM in each nucleoside triphosphate. This DNA was cut with *BamHI* then run on a 6 percent acrylamide gel. The vector fragment was isolated from the gel by electroelution then resuspended in 20 µl dH₂O. 20 ng of this vector was ligated with 20 ng of the 9 bp fragment synthesized above for 4 hours at room temperature. One-fifth of the ligation mix was used to transform *E. coli* strain 294 to ampicillin resistance (on LB +20 µg/ml amp plates). Plasmids from the transformants were examined by a quick screen procedure (22). One plasmid, pPGK-39 was selected for sequence analysis. 20 µg of this plasmid was digested with *XbaI*, ethanol precipitated then treated with 1000 units of bacterial alkaline phosphatase at 68°C for 45 min. The DNA was 3X phenol-chloroform extracted, then ethanol precipitated. The dephosphorylated ends were then labelled in a 20 µl reaction containing 200 µCi of [³²P] ATP and 10 units of T₄ polynucleotide kinase. The plasmid was cut with *SaI* and run on a 6 percent acrylamide gel.

The labelled insert band was isolated from the gel and sequenced by the chemical degradation method (25). The DNA sequence at the 3'-end of this promoter piece was as expected. Step 2 (Figure 4)

Construction of 312 bp *PvuI*-to-*EcoRI* PGK promoter fragment

25 µg of pPGK-39 (Fig. 3) was simultaneously digested with *SaI* and *XbaI* (5 units each) then electrophoresed on a 6 percent gel. The 390 pb band containing the 39 bp promoter piece was isolated by electroelution. The resuspended DNA was restricted with *Sau3A* then electrophoresed on an 8 percent acrylamide gel. The 39 pb PGK promoter band was isolated by electroelution. This DNA contained 39 bp of the 5' end of the PGK promoter on a *Sau3A*-to-*XbaI* fragment.

25 µg of pB1 was restricted with *PvuI* and *KpnI* then electrophoresed on a 6 percent gel. The .8 kpb band of DNA was isolated by electroelution, then restricted with *Sau3A* and electrophoresis on a 6 percent gel. The 265 bp band from the PGK promoter (Figure 1) was isolated by electroelution.

This DNA was then ligated with the 39 bp promoter fragment from above for two hours at room temperature. The ligation mix was restricted with *XbaI* and *PvuI* then electrophoresed on a 6 percent acrylamide gel. The 312 bp *XbaI*-to-*PvuI* restriction fragment was isolated by electroelution, then added to a ligation mix containing 200 ng of pBR322 [previously isolated missing the 162 *PvuI*-to-*PstI* restriction fragment] and 200 ng of the *XbaI*-to-*pstI* *LeIFA* cDNA gene previously isolated from 20 µg of pLEIFtrpA. This 3-factor-ligation mix was used to transform *E. coli*

strain 294 to tetracycline resistance. Transformant clones were miniscreened and one of the colonies, pPGK-300 was isolated as having 304 bp of PGK 5'-flanking DNA fused to the *LeIFA* gene in a pBR322 based vector. The 5' end of the *LeIFA* gene has the following sequence: 5'-CTAGAAATTC 3', thus fusion of the *XbaI* site from the PGK promoter fragment into this sequence allows for the addition to the *XbaI* site an *EcoRI* site. pPGK-300 thus contains part of the PGK promoter isolated in a *PvuI*-to-*EcoRI* fragment.

Step 4 (Fig. 5)

Construction of a 1500 pb *EcoRI*-to-*EcoRI* PGK promoter fragment

10 µg of pB1 was digested with *PvuI* and *EcoRI* and run on a 6 percent acrylamide gel. The 1.3 kb *PvuI*-to-*EcoRI* DNA band from the PGK 5'-flanking DNA was isolated by electroelution. 10 µg of pPGK-300 was digested with *EcoRI* and *PvuI* and the 312 bp promoter fragment was isolated by electroelution after electrophoresing the digestion mix on a 6 percent gel. 5 µg of pFRL4 was cut with *EcoRI*, ethanol precipitated then treated with bacterial alkaline phosphatase at 68° for 45 minutes. After 3X phenol/chloroform treating the DNA, ethanol precipitation, and resuspension in 20 ml of dH₂O; 200 ng of the vector was ligated with 100 ng of 312 bp *EcoRI*-to-*PvuI* DNA from pPGK-300 and 100 ng of *EcoRI*-to-*PvuI* DNA from pB1. The ligation mix was used to transform *E. coli* strain 294 to ampicillin resistance. From one of the Ap^R colonies was obtained pPGK-1500. This plasmid contains the 1500 bp PGK promoter fragment at an *EcoRI*-to-*EcoRI* or *HindIII*-to-*EcoRI* piece of DNA.

Construction of expression vector (Figure 6)

20 µg of pFRL4 was digested with *HindIII* and *BglII* then electrophoresed on a 6 percent acrylamide gel. The 230 bp fragment from the *TRP1* gene containing part of the structural gene and the 3' untranslated region (28) was isolated by electroelution from the gel slice. This is the yeast terminator restriction fragment.

10 µg of pHS94 was restricted with *HindIII* and *EcoRI*, run on a 6 percent acrylamide gel. The 870 bp band representing the HBsAg gene was isolated by electroelution.

3 µg of the HBsAg gene was ligated with 1 µg of the *TRP1* "terminator" for 2 hours at room temperature. This solution was then restricted with *EcoRI* and *BglII* and electrophoresed on a 6 percent acrylamide gel. The 1.1 kb band corresponding to 5'-HBsAg/*TRP1*-3' DNA fragment was isolated by electroelution. 50 µg of pPGK-1500 was restricted with *HindIII* and *EcoRI* then electrophoresed on a 6 percent acrylamide gel. The 1.5 kbp PGK promoter fragment was isolated by electroelution. 10 µg of pCV13 was restricted with *HindIII* and *BamHI* then electrophoresed on a 1 percent agarose gel. The large vector fragment was isolated by electroelution. 0.9 µg of pCV13 (*HindIII* to *BamHI*), 150 ng of *HindIII* to *EcoRI* PGK promoter fragment, and 100 ng of *EcoRI* to *BglII*

HbsAg/TRP1 fusion were ligated for 12 hours at 16°C and then used to transform *E. coli* strain 294 to ampicillin resistance. Miniscreen analysis of a number of transformants indicated that some colonies contained the proper vector construction with promoter-HBsAg structural gene-TRP1 terminator. Several of these plasmids were used to transform yeast to Leu⁺.

Transformation of yeast and assay for HbsAg

Yeast strain XV610-8C was grown in YPD (29), prepared for transformation using standard procedures (20, 21), and transformed to leucine prototrophy (Leu⁺) using plasmid pCV13 or pYeHBs on minimal YNB(-leu) (See Strains and Media). Transformant colonies were prepared for HBsAg radioimmune assay (Abbott Labs) as follows:

(1) Grow 10 mls of yeast in YNB-leucine at 30°C with aeration to an absorbance at 660 mμ of 1.0.

(2) Spin culture 5 min at 5000 xg. Discard supernatant.

(3) Resuspend cells in 500 μl of PBS (20 mM sodium phosphate at pH=7 plus 0.14 M NaCl), add 1.5 gram sterile glass beads (.45—.50 mm) and vortex 5 min (keeping cold by putting on ice intermittently).

(4) Spin cell extract 5,000 kg for 3 min at 4°C. Use 200 μl of cell extract for standard radioimmune assay. Cell extract was diluted using PBS.

Evidence for HBsAg expression in yeast by pYeHBs

pYeHBs and pCV13 were used to transform yeast strain XV610-8C to leucine prototrophy in YNB-leu minimal media. The presence of the plasmid was verified by growing the yeast on plates with no leucine selection (YPD) to colonies followed by replica plating to YNB(-leucine) plates (2 percent agar). Fifty to 60 percent of the colonies that grew on YEPD grew on YNB-leu demonstrating that 50—60 percent of yeast contained pCV13 or pYeHBs. It should be noted that a Leu⁺ revertant would show growth of all colonies on YNB-leu. pCV13 stability in the yeast was no greater than pYeHBs, suggesting that the production of HBsAg (as discussed infra.) does not put pressure on cells to restrict copy number.

Transformant yeast were grown in liquid leucine selection media (YNB-leu) then broken open by vortexing with a glass bead suspension (infra.). A radioimmune assay was used to assess HBsAg production in the cleared yeast extract. The 22 nm HBsAg particle is roughly 1000 times more antigen than the HBsAg monomers alone and we used antibody prepared against this particle. The RIA on the yeast extract indicates the production of HBsAg from pYeHBs in yeast. [pCV13 transformed yeast extracts produce no HBsAg antigen material.]

Characterization of HBsAg in yeast

1) 200 μl of yeast extract prepared as described above was layered on top of a 5 ml linear density

gradient consisting of 5—20 percent sucrose (w/v) in 20 mM Tris-HCl (pH 7.4), 0.5 mM EDTA, and 0.5M NaCl then centrifuged in a SW50.1 rotor at 45,000 rpm for 2 hours. Fractions were collected and assayed for HBsAg by radioimmune assay.

2) 200 μl of extract from the same source as above was layered on top of a 5 ml solution containing 20 mM Tris-HCl (pH 7.4), 0.5 mM EDTA, and CsCl (density 1.2 g/cc) then centrifuged in a SW50.1 rotor at 45,000 rpm for 70 hours. HBsAg was assayed as described above and the density of CsCl was determined by recording the refractive index of each gradient fraction.

Hepatitis surface antigen is synthesized and secreted from liver cells as a particle (22 nm particle). In the construction described above, only the coding region representing the mature structural gene plus some 3' untranslated sequences were included. We assessed the particulate nature of the hepatitis surface antigen monomer within the yeast cell. To this end, aliquots of a yeast cell extract containing HBsAg were subjected to sedimentation velocity and sedimentation equilibrium analysis. As shown in Figure 7, the hepatitis surface antigen synthesized in yeast cell has a sedimentation rate that is virtually identical to that of the "22 nm particle" form of HBsAg obtained from a cell line (PLCWIll) secreting authentic 22 nm particles.

HBsAg synthesized in yeast has a buoyant density of 1.18 g/cm³ as determined by sedimentation equilibrium analysis. This value is slightly lower than that of HBsAg synthesized in the infected liver cell.

Vaccine preparation

Vaccines incorporating the HBsAg produced as herein described, can be prepared according to known methods, wherein said HBsAg is combined in admixture with a suitable vehicle. Suitable vehicles include, for example, saline solutions, various known adjuvants, or other additives recognized in the art for use in compositions applied to prevent viral infections. Such vaccines will contain an effective amount of the HBsAg hereof and a suitable amount of vehicle in order to prepare a vaccine useful for effective administration to the host. Attention is also directed to *New Trends and Developments in Vaccines*. Editors: A. Voller and H. Friedman, University Park Press, Baltimore, 1978, which is hereby incorporated by reference, for further background details on the preparation of vaccines.

Bibliography

1. Broach, J. R., Strathern, J. N., and Hicks, J. B. *Gene* 8, 121—133 (1979).
2. Ratzkin, B., and Carbon, J. *Proc. Natl. Acad. Sci. U.S.A.* 74, 487—491 (1977).
3. Chinault, A. C., and Carbon, J. *Gene* 5 111—126 (1979).
4. Hinnen, A., Hicks, J. B., and Fink, G. R. *Proc. Natl. Acad. Sci. U.S.A.* 75, 1929—1933 (1978).
5. Hitzeman, R. A., Clarke, L., and Carbon, J. J. *Biol. Chem.* 255, 12073 (1980).

6. Hess, B., Boiteux, A., and Kruger, J. *Adv. Enzyme Regul.* 7, 149—167 (1968).

7. Holland, J. J., and Holland, J. P. *Biochemistry* 17, 4900—4907 (1978).

8. Bostian, K. A., Lemire, J. M., Cannon, L. E., and Halvorson, H. O. *Proc. Natl. Acad. Sci. U.S.A.* 77, 4504—4508 (1980).

9. Abstracts of papers presented at the 1981 meeting on *The Molecular Biology of Yeast* (August 11—August 16, 1981) Cold Spring Harbor Laboratory, Cold Spring Harbor, New York.

10. Chambon, P. *Ann. Rev. Biochem.* 44, 613—638 (1975).

11. Goeddel, D. Y., Shepard, H. M., Yelverton, E., Leung, D., and Crea, R. *Nucleic Acids Research* 8, 4057—4073 (1980).

12. Hitzeman, R. A. *et al. Nature*, 293 717—722 (1981).

13. Goeddel, D. Y. *et al. Nature* 287 411—416 (1980).

14. P. Valenzuela, *et al. Nature*, 280, 815—819, (1979).

15. P. Charnay *et al. Proc. Natl. Acad. Sci. (U.S.A.)* 76, 2222—2226 (1979).

16. H. Jacobsen *et al. Eur. J. Biochem.* 45, 623. (1974).

17. Clarke, L., and Carbon, J. *Cell* 9, 91—99 (1976).

18. Davis, R. W., Thomas, M., Cameron, J., St. John, T. P., Scherer, S., and Padgett, R. A. *Methods in Enzymology* 65, 404—411.

19. Clark, L., and Carbon, J. *Proc. Natl. Acad. Sci. U.S.A.* 72, 4361—4365 (1975).

20. Beggs, J. D. *Nature* 275, 104—109 (1978).

21. Hinnen, A., Hicks, J. B., and Fink, G. R. *Proc. Natl. Acad. Sci. U.S.A.* 75, 1929—1933 (1978).

22. Birnboim, H. C., and Poly. J. *Nucleic Acids Res.* 7, 1513—1523.

23. Backman, K., Ptashne, M., and Gilbert, W. *Proc. Natl. Acad. Sci. U.S.A.* 73, 4174—4178 (1976).

24. Miller, J. H. *Experiments in Molecular Genetics*, pp. 431—433, Cold Spring Harbor Laboratory, Cold Spring Harbor, N. Y.

25. Maxam, A. M., and Gilbert, W. *Methods in Enzymol.* 65, 490—565 (1980).

26. Crea, R. and Horn, T. *Nucleic Acids Res.* 8, 2331—2348 (1980).

27. Bolivar, F., Rodriguez, R. L., Green, P. Y., Betlach, M. C., Heyneker, H. L., Boyer, H. W., Crosa, Y. H., and Falkow, S. *Gene* 2, 95—113 (1977).

28. Tschumper, G., and Carbon J. *Gene* 10, 157—166 (1980).

29. Laboratory Manual for a course *Methods in Yeast Genetics* Cold Spring Harbor Laboratory, Sherman, Fink, and Hicks, Cold Spring Harbor, New York.

Claims for the Contracting States: BE, CH, DE, FR, GB, IT, LI, LU, NL, SE

1. A DNA expression vector capable of replication and phenotypic selection in yeast host strain comprising a promoter compatible with a yeast host strain and a DNA sequence encoding

hepatitis B surface antigen (HBsAg) and lacking any sequence encoding HBsAg precursor sequence, said DNA sequence being positioned with appropriate translational start and stop signals in said vector under control of said promoter such that in a transformant yeast strain it is expressed to produce mature hepatitis B surface antigen in discrete particle form.

2. A DNA vector according to claim 1 wherein the promoter is derived from a yeast glycolytic enzyme gene, acid phosphatase gene, or a gene whose 5'-flanking regions contain mutations resulting in unusually high expression levels.

3. A DNA vector according to claim 2 wherein the promoter is derived from the yeast PGK gene.

4. A yeast strain transformed with the DNA expression vector according to any one of claims 1, 2 and 3.

5. A yeast strain according to claim 4 obtained by transforming a *leu2* autotrophic yeast strain, the vector containing a *LEU2* gene for phenotypic selection in yeast.

6. A fermentation culture comprising a transformed yeast according to claim 4 or claim 5.

7. A method of producing hepatitis B surface antigen which comprises growing a culture according to claim 6 so as to produce said antigen, and recovering the antigen therefrom in particle form.

8. A method of producing hepatitis B surface antigen in particle form suitable for use in conferring immunogenicity to hepatitis B virus in a susceptible human which comprises:

a) providing a DNA transfer vector capable of replication and phenotypic selection in yeast host strains;

b) providing a DNA fragment comprising a promoter compatible with a yeast host strain;

c) providing a DNA fragment encoding hepatitis B surface antigen and lacking any sequence encoding HBsAg precursor sequence;

d) assembling the fragments of steps a), b) and c) to form a replicable expression vector wherein said sequence of step c) is under control of said promoter, with appropriate translational start and stop signals, such that it is expressible to produce mature hepatitis B surface antigen;

e) transforming a yeast strain with the vector of step d);

f) allowing the yeast transformant to grow until said hepatitis B surface antigen is produced therein; and

g) recovering said hepatitis B surface antigen in discrete particle form.

9. A method according to claim 8 wherein the DNA sequence of step c) comprises, in order from the 5' end of its coding strand, an ATG translational start codon, the remaining nucleotides encoding mature hepatitis B surface antigen of the hepatitis B genome, and translational stop signal(s).

10. A method according to claim 8 or claim 9 wherein the promoter of step b) is derived from the yeast PGK promoter region.

11. A method according to any one of claims 8

to 10 wherein the vector contains a *LEU2* gene for phenotypic selection in yeast, and the yeast strain is a *leu2* auxotrophic yeast strain.

Claims for the Contracting State: AT

1. A method which comprises producing a DNA expression vector capable of replication and phenotypic selection in yeast host strain comprising a promoter compatible with a yeast host strain and a DNA sequence encoding hepatitis B surface antigen (HBsAg) and lacking any sequence encoding HBsAg precursor sequence, said DNA sequence being positioned with appropriate translational start and stop signals in said vector under control of said promoter such that in a transformant yeast strain it is expressed to produce mature hepatitis B surface antigen in discrete particle form.

2. A method according to claim 1 wherein the promoter is derived from a yeast glycolytic enzyme gene, acid phosphatase gene, or a gene whose 5'-flanking regions contain mutations resulting in unusually high expression levels.

3. A method according to claim 2 wherein the promoter is derived from the yeast PGK gene.

4. A method which comprises transforming a yeast strain with a DNA expression vector according to any one of claims 1, 2 and 3.

5. A method according to claim 4 which comprises transforming a *leu2* auxotrophic yeast strain, the vector containing a *LEU2* gene for phenotypic selection in yeast.

6. A method which comprises producing a fermentation culture from a transformed yeast according to claim 4 or claim 5.

7. A method of producing hepatitis B surface antigen which comprises growing a culture according to claim 6 so as to produce said antigen, and recovering the antigen therefrom in particle form.

8. A method of producing hepatitis B surface antigen in particle form suitable for use in conferring immunogenicity to hepatitis B virus in susceptible human which comprises:

a) providing a DNA transfer vector capable of replication and phenotypic selection in yeast host strains;

b) providing a DNA fragment comprising a promoter compatible with a yeast host strain;

c) providing a DNA fragment encoding hepatitis B surface antigen and lacking any sequence encoding HBsAg precursor sequence;

d) assembling the fragments of steps a), b) and c) to form a replicable expression vector wherein said sequence of step c) is under control of said promoter, with appropriate translational start and stop signals, such that it is expressible to produce mature hepatitis B surface antigen;

e) transforming a yeast strain with the vector of step d);

f) allowing the yeast transformant to grow until said hepatitis B surface antigen is produced therein; and

g) recovering said hepatitis B surface antigen in discrete particle form.

9. A method according to claim 8 wherein the DNA sequence of step c) comprises, in order from the 5' end of its coding strand, an ATG translational start codon, the remaining nucleotides encoding hepatitis B surface antigen of the hepatitis B genome, and translational stop signal(s).

10. A method according to claim 8 or claim 9 wherein the promoter of step b) is derived from the yeast PGK promoter region.

11. A method according to any one of claims 8 to 10 wherein the vector contains a *LEU2* gene for phenotypic selection in yeast, and the yeast strain is a *leu2* auxotrophic yeast strain.

Patentansprüche für die Vertragsstaaten BE, CH, DE, FR, GB, IT, LI, LU, NL, SE:

1. DNA Expressionsvektor, der für die Replikation und phänotypische Selektion in Hefewirtstämchen geeignet ist, umfassend einen Promotor, der mit einem Hefewirtstamm verträglich ist und eine DNA Sequenz, die Hepatitis B Oberflächenantigen (HBsAg) kodiert und der jede Sequenz fehlt, die eine HBsAg Vorläufersequenz kodiert, wobei die genannte DNA Sequenz im genannten Vektor mit entsprechenden Translationsstart- und Stoppsignalen unter der Steuerung des genannten Promotors positioniert ist, sodaß sie in einem Transformantestamm exprimiert wird, um reifes Hepatitis B Oberflächenantigen in diskreter Teilchenform zu produzieren.

2. DNA Vektor nach Anspruch 1, worin der Promotor von einem glykolytischen Hefeenzymgen, Säurephosphatasegen oder einem Gen abgeleitet ist, dessen 5'-Flankenbereiche Mutationen enthalten, die zu ungewöhnlich hohen Expressionswerten führen.

3. DNA Vektor nach Anspruch 2, worin der Promotor vom Hefe PGK Gen abgeleitet ist.

4. Hefestamm, der mit dem DNA Expressionsvektor nach einem der Ansprüche 1, 2 und 3 transformiert ist.

5. Hefestamm nach Anspruch 4, der durch Transformieren eines *leu2* auxotrophen Hefestammes erhalten wird, wobei der Vektor ein *LEU2* Gen für die phänotypische Selektion in Hefe enthält.

6. Fermentationskultur, umfassend eine transformierte Hefe nach Anspruch 4 oder Anspruch 5.

7. Verfahren zur Herstellung von Hepatitis B Oberflächenantigen, das das Züchten einer Kultur nach Anspruch 6, um das genannte Antigen herzustellen und die Gewinnung des Antigens aus der Kultur in Teilchenform umfaßt.

8. Verfahren zur Herstellung von Hepatitis B Oberflächenantigen in Teilchenform, das für die Verleihung von Immunogenizität gegen Hepatitis B Virus in einem anfälligen Menschen geeignet ist, umfassend:

a) Bereitstellen eines DNA Transfervektors,

zur Replikation und phänotypische Selektion in Hefewirtsstämmen fähig ist;

b) Bereitstellen eines DNA Fragmentes, das einen mit einem Hefewirtsstamm verträglichen Promotor enthält;

c) Bereitstellen eines DNA Fragmentes, das Hepatitis B Oberflächenantigen kodiert und dem jede Sequenz fehlt, die eine HBsAg Vorläufersequenz kodiert;

d) Vereinigen der Fragmente der Schritte a), b) und c), um einen replizierbaren Expressionsvektor zu bilden, worin die genannte Sequenz von Schritt c) unter der Steuerung des genannten Promotors mit geeigneten Translationsstart- und Stoppsignalen steht, sodaß sie exprimierbar ist, um reifes Hepatitis B Oberflächenantigen zu produzieren;

e) Transformieren eines Hefestammes mit dem Vektor von Schritt d);

f) Kultivieren des Hefetransformanten, bis das genannte Hepatitis B Oberflächenantigen darin produziert ist;

g) Gewinnen des genannten Hepatitis B Oberflächenantigens in diskreter Teilchenform.

9. Verfahren nach Anspruch 8, worin die DNA Sequenz aus Schritt c) in Reihenfolge vom 5'-Ende ihres Kodierungsstranges an einen ATG Translationsstartcodon, die verbleibenden Nucleotide, die das reife Hepatitis B Oberflächenantigen des Hepatitis B Genoms kodieren, und (ein) Translations-stoppsignal(e) enthält.

10. Verfahren nach Anspruch 8 oder 9, worin der Promotor von Schritt b) vom Hefe PGK Promotorbereich abgeleitet ist.

11. Verfahren nach einem der Ansprüche 8 bis 10, worin der Vektor ein *LEU2* Gen für die phänotypische Selektion in Hefe enthält und der Hefestamm ein *leu2* auxotropher Hefestamm ist.

Patentansprüche für den Vertragsstaat AT:

1. Verfahren, das die Herstellung eines DNA Expressionsvektors umfaßt, der für die Replikation und phänotypische Selektion in Hefewirtsstämmen geeignet ist, umfassend einen Promotor, der mit einem Hefewirtsstamm verträglich ist und eine DNA Sequenz, die Hepatitis B Oberflächenantigen (HBsAg) kodiert und der jede Sequenz fehlt, die eine HBsAg Vorläufersequenz kodiert, wobei die genannte DNA Sequenz im genannten Vektor mit entsprechenden Translationsstart- und Stoppsignalen unter der Steuerung des genannten Promotors positioniert ist, sodaß sie in einem Transformantheferstamm exprimiert wird, um reifes Hepatitis B Oberflächenantigen in diskreter Teilchenform zu produzieren.

2. Verfahren nach Anspruch 1, worin der Promotor von einem glycolytischen Hefeenzymgen, Säurephosphatasegen oder einem Gen abgeleitet ist, dessen 5'-Flankenbereiche Mutationen enthalten, die zu ungewöhnlich hohen Expressionswerten führen.

3. Verfahren nach Anspruch 2, worin der Promotor vom Hefe PGK Gen abgeleitet ist.

4. Verfahren, das die Transformation eines

Hefestammes mit einem DNA Expressionsvektor nach einem der Ansprüche 1, 2 und 3 umfaßt.

5. Verfahren nach Anspruch 4, das die Transformation eines *leu2* auxotrophen Hefestammes umfaßt, wobei der Vektor ein *LEU2* Gen für die phänotypische Selektion in Hefe enthält.

6. Verfahren, das die Herstellung einer Fermentationskultur aus einer transformierten Hefe nach Anspruch 4 oder Anspruch 5 umfaßt.

7. Verfahren zur Herstellung von Hepatitis B Oberflächenantigen, das das Züchten einer Kultur nach Anspruch 6, um das genannte Antigen herzustellen und die Gewinnung des Antigens aus der Kultur in Teilchenform umfaßt.

8. Verfahren zur Herstellung von Hepatitis B Oberflächenantigen in Teilchenform, das für die Verleihung von Immunogenizität gegen Hepatitis B Virus in einem anfälligen Menschen geeignet ist, umfassend:

a) Bereitstellen eines DNA Transfervektors, der zur Replikation und phänotypische Selektion in Hefewirtsstämmen fähig ist;

b) Bereitstellen eines DNA Fragmentes, das einen mit einem Hefewirtsstamm verträglichen Promotor enthält;

c) Bereitstellen eines DNA Fragmentes, das Hepatitis B Oberflächenantigen kodiert und dem jede Sequenz fehlt, die eine HBsAg Vorläufersequenz kodiert;

d) Vereinigen der Fragmente der Schritte a), b) und c), um einen replizierbaren Expressionsvektor zu bilden, worin die genannte Sequenz von Schritt c) unter der Steuerung des genannten Promotors mit geeigneten Translationsstart- und Stoppsignalen steht, sodaß sie exprimierbar ist, um reifes Hepatitis B Oberflächenantigen zu produzieren;

e) Transformieren eines Hefestammes mit dem Vektor von Schritt (d);

f) Kultivieren des Hefetransformanten, bis das genannte Hepatitis B Oberflächenantigen darin produziert ist;

g) Gewinnen des genannten Hepatitis B Oberflächenantigens in diskreter Teilchenform.

9. Verfahren nach Anspruch 8, worin die DNA Sequenz aus Schritt c) in Reihenfolge vom 5'-Ende ihres Kodierungsstranges an einen ATG Translationsstartcodon, die verbleibenden Nucleotide, die das reife Hepatitis B Oberflächenantigen des Hepatitis B Genoms kodieren, und (ein) Translations-stoppsignal(e) enthält.

10. Verfahren nach Anspruch 8 oder 9, worin der Promotor von Schritt b) vom Hefe PGK Promotorbereich abgeleitet ist.

11. Verfahren nach einem der Ansprüche 8 bis 10, worin der Vektor ein *LEU2* Gen für die phänotypische Selektion in Hefe enthält und der Hefestamm ein *leu2* auxotropher Hefestamm ist.

Revendications pour les Etats Contractants BE, CH, DE, FR, GB, IT, LI, LU, NL, SE

1. Vecteur d'expression d'ADN capable d'une réplication et d'une sélection phénotypique dans

une souche hôte de levure comprenant un promoteur compatible avec une souche hôte de levure et une séquence d'ADN codant l'antigène de surface de l'hépatite B (HBsAg) et manquant de toute séquence codant la séquence précurseur de HBsAg, ladite séquence d'ADN étant placée avec des signaux appropriés de début et de fin de translation dans ledit vecteur sous le contrôle dudit promoteur de manière que dans une souche de levure transformante, elle s'exprime pour produire l'antigène de surface de l'hépatite B mature sous forme de particules distinctes.

2. Vecteur d'ADN selon la revendication 1, où le promoteur est dérivé d'un gène de l'enzyme glycolytique de la levure, d'un gène de phosphatase acide, ou d'un gène dont les régions flanquant 5' contiennent des mutations ayant pour résultat des niveaux inhabituellement élevés d'expression.

3. Vecteur d'ADN selon la revendication 2, où le promoteur est dérivé du gène PGK de la levure.

4. Souche de levure transformée par le vecteur d'expression d'ADN selon l'une quelconque des revendications 1, 2 et 3.

5. Souche de levure selon la revendication 4, obtenue par transformation d'une souche de levure auxotrophe de *leu2*, le vecteur contenant un gène *LEU2* pour la sélection phénotypique dans la levure.

6. Culture en fermentation comprenant une levure transformée selon la revendication 4 ou la revendication 5.

7. Méthode de production de l'antigène de surface de l'hépatite B qui comprend la croissance d'une culture selon la revendication 6, afin de produire ledit antigène, et la récupération de l'antigène sous forme de particules.

8. Méthode de production de l'antigène de surface de l'hépatite B sous forme de particules approprié à une utilisation pour conférer une immunogénicité au virus de l'hépatite B chez un être humain sensible, qui consiste à:

a) prévoir un vecteur de transfert d'ADN capable d'une répllication et d'une sélection phénotypique chez des souches hôtes de levure;

b) prévoir un fragment d'ADN comprenant un promoteur compatible avec une souche hôte de levure;

c) prévoir un fragment d'ADN codant l'antigène de surface de l'hépatite B et manquant de toute séquence codant la séquence précurseur de HBsAg;

d) assembler les fragments des étapes a), b) et c) pour former un vecteur d'expression répliquable, où ladite séquence de l'étape c) est sous le contrôle dudit promoteur avec signaux appropriés de début et de fin de translation, qui peut s'exprimer pour produire l'antigène de surface de l'hépatite B mature;

e) transformer une souche de levure par le vecteur de l'étape d);

f) permettre au transformant de la levure de

croître jusqu'à ce que ledit antigène de surface de l'hépatite B y soit produit; et

g) récupérer ledit antigène de surface de l'hépatite B sous forme de particules distinctes.

9. Méthode selon la revendication 8, où ladite séquence d'ADN de l'étape c) comprend, dans l'ordre à partir de l'extrémité 5' de son brin codant, un codon de début de translation de ATG, les nucléotides résiduels codant l'antigène de surface de l'hépatite B mature du génome de l'hépatite B et le ou les signaux d'arrêt de translation.

10. Méthode selon la revendication 8 ou la revendication 9, où le promoteur de l'étape b) est dérivé de la région du promoteur PGK de la levure.

11. Méthode selon l'une quelconque des revendications 8 à 10, où le vecteur contient un gène *LEU2* pour la sélection phénotypique dans la levure, et la souche de levure est une souche de levure auxotrophe *leu2*.

Revendications pour l'Etat Contractant AT

1. Méthode qui comprend la production d'un vecteur d'expression d'ADN capable d'une répllication et d'une sélection phénotypique dans une souche hôte de levure, comprenant un promoteur compatible avec une souche hôte de levure et une séquence d'ADN codant l'antigène de surface de l'hépatite B (HBsAg) et manquant de toute séquence codant la séquence précurseur de HBsAg, ladite séquence d'ADN étant placée avec des signaux appropriés de début et de fin de translation dans ledit vecteur sous le contrôle dudit promoteur, de manière que dans une souche de levure transformante, elle s'exprime pour produire l'antigène de surface de l'hépatite B mature sous forme de particules distinctes.

2. Méthode selon la revendication 1, où le promoteur est dérivé d'un gène de l'enzyme glycolytique de la levure, d'un gène de phosphatase acide, ou d'un gène dont les régions flanquant 5' contiennent des mutations ayant pour résultat des niveaux inhabituellement élevés d'expression.

3. Méthode selon la revendication 2, où le promoteur est dérivé du gène PGK de la levure.

4. Méthode qui comprend la transformation d'une souche de levure par un vecteur d'expression d'ADN selon l'une quelconque des revendications 1, 2 et 3.

5. Méthode selon la revendication 4, qui comprend la transformation d'une souche de levure auxotrophe de *leu2*, le vecteur contenant un gène *LEU2* pour la sélection phénotypique dans la levure.

6. Méthode qui comprend la production d'une culture en fermentation à partir d'une levure transformée selon la revendication 4 ou la revendication 5.

7. Méthode de production de l'antigène de surface de l'hépatite B qui comprend la croissance d'une culture selon la revendication 6,

afin de produire l'antigène, et la récupération de l'antigène sous forme de particules.

8. Méthode de production de l'antigène de surface de l'hépatite B sous forme de particules approprié à une utilisation pour conférer une immunogénicité au virus de l'hépatite B chez un être humain sensible, qui consiste à:

a) prévoir un vecteur de transfert d'ADN capable d'une réplication et d'une sélection phénotypique chez des souches hôtes de levure;

b) prévoir un fragment d'ADN comprenant un promoteur compatible avec une souche hôte de levure;

c) prévoir un fragment d'ADN codant l'antigène de surface de l'hépatite B et manquant de toute séquence codant la séquence précurseur de HBsAg;

d) assembler les fragments des étapes a), b) et c) pour former un vecteur d'expression répliquable, où ladite séquence de l'étape c) est sous le contrôle dudit promoteur avec des signaux appropriés de début et de fin de translation, qui peut s'exprimer pour produire l'antigène de surface de l'hépatite B mature;

e) transformer une souche de levure par le vecteur de l'étape d);

f) permettre au transformant de la levure de croître jusqu'à ce que ledit antigène de surface de l'hépatite B y soit produit; et

g) récupérer ledit antigène de surface de l'hépatite B sous forme de particules distinctes.

9. Méthode selon la revendication 8, où ladite séquence d'ADN de l'étape c) comprend, dans l'ordre à partir de l'extrémité 5' de son brin codant, un codon de début de translation de ATG, les nucléotides résiduels codant l'antigène de surface de l'hépatite B mature du génome de l'hépatite B et le ou les signaux d'arrêt de translation.

10. Méthode selon la revendication 8 ou la revendication 9, où le promoteur de l'étape b) est dérivé de la région du promoteur PKG de la levure.

11. Méthode selon l'une quelconque des revendications 8 à 10, où le vecteur contient un gène *LEU2* pour la sélection phénotypique dans la levure, et la souche de levure est une souche de levure auxotrophe *leu2*.

25

30

35

40

45

50


55

60

65

14

FIG. A



THE INSERTION OF AN EcoRI SITE IN THE 5' FLANKING DNA OF THE 3-PHOSPHOGLYCERATE GENE OF YEAST




Fig. 1.

DNA SEQUENCE OF THE 5' END
OF THE YEAST 3-PHOSPHOGLYCERATE KINASE
STRUCTURAL GENE AND FLANKING DNA

5'-----GATCATAAGGAAGTAATATATCTACTCTTTTACAAACAATATAAACA ATG TCT TTA TCT TCA AAG TTG CTC CTC
-40 -30 -20 -10 -1 MET SER LEU SER SER LYS LEU LEU VAL

FIG. 2.




FIG. 3.




FIG. 4.




Fig. 5.




FIG. 6.




FIG. 7